Role of Biomarkers in Cancer Diagnosis and Therapeutics

個数：

予約

Role of Biomarkers in Cancer Diagnosis and Therapeutics

Talegaonkar, Sushama (EDT)/ Kumar, Lalit (EDT)/ Gugulothu, Dalapathi (EDT)

ウェブストア価格 ¥44,211（本体¥40,192）
Academic Press Inc（2026/05発売）
外貨定価 US$ 200.00
ポイント 401pt

現在予約受付中です。出版後の入荷・発送となります。
（重要：表示されている発売日は予定となり、発売が延期、中止、生産限定品で商品確保ができないなどの理由により、ご注文をお取消しさせていただく場合がございます。予めご了承ください。）

●3Dセキュア導入とクレジットカードによるお支払いについて

【入荷遅延について】
世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。

◆画像の表紙や帯等は実物とは異なる場合があります。

◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
また、洋書販売価格は、ご注文確定時点での日本円価格となります。
ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。

製本 Paperback:紙装版/ペーパーバック版／ページ数 550 p.
言語 ENG
商品コード 9780443440410

Full Description

Role of Biomarkers in Cancer Diagnosis and Therapeutics offers a thorough exploration of the critical roles biomarkers play in cancer detection, diagnosis, monitoring, and therapy. The book is divided into three parts: the first focuses on established and emerging biomarkers like PSA and CEA, detailing their biochemical characteristics and clinical relevance. The second section examines metabolic pathways utilized by cancer cells, highlighting key enzymes and their therapeutic potential. The final part discusses innovative strategies targeting cell cycle checkpoints and DNA repair mechanisms, including synthetic lethality through PARP inhibitors. This essential resource provides researchers and clinicians with insights into novel metabolic targets and cutting-edge treatment strategies. By addressing current applications and future challenges, including the integration of AI and multi-omics approaches, the book equips readers with actionable knowledge to advance personalized cancer care and navigate the dynamic landscape of oncology.

I. Biomarkers in Cancer Diagnosis and Treatment
1. Prostate-Specific Antigen (PSA)
2. Carcinoembryonic Antigen (CEA)
3. Tissue Polypeptide-Specific Antigen (TPS) CA72-4
4. Carbohydrate Antigen 19-9 (CA19-9)
5. Carbohydrate Antigen 125 (CA-125)
6. Carbohydrate Antigen 72-4 (CA72-4)
7. Aminopeptidase N
8. Alkaline Phosphatase
9. CD26/Dipeptidyl Peptidase (DPP)4
10. Genetic Biomarkers in Cancer
11. Immunology Biomarkers in Cancer
12. Microbiome Biomarkers in Cancer
13. Glycobiology Biomarkers in Cancer
14. Epigenetic Biomarkers in Cancer

II. Metabolic Targets and Cancer Therapeutics
15. Introduction to Metabolic Targets and Autophagy
16. Glucose Metabolism - Hexokinase-2 (HK2), Lactate Dehydrogenase A (LDHA), Pyruvate Kinase M2 Isoform (PKM2), Pyruvate Dehydrogenase (PDK), Glucose Transporter, Enolase 1 (ENO1), and Monocarboxylate Transporter (MCT1)
17. Nucleic Acid Metabolism - Folate Cycle, Nucleotide Incorporation (DNA Polymerase/Ribonucleotide Reductase (RNR)), Deoxynucleotide Synthesis (RNR), and Thymidine Synthesis (TYMS)
18. Amino Acid Metabolism - Arginine and Asparagine, Serine/Threonine Protein Kinase (Glycogen Synthase Kinase-3 (GSK-3))
19. Glucose and Amino Acid Metabolism - Isocitrate Dehydrogenase-1 (IDH-1)
20. Glucose, Nucleic Acid, Fatty Acid, and Amino Acid Metabolism - Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH)

III. Miscellaneous Cancer Therapeutic Approaches
21. Targeting DNA Repair Pathways - O-6-Methylguanine-DNA Methyltransferase (MGMT), Base Excision Repair, Double Strand Breaks Repair, and mtDNA Repair
22. Cell Cycle Inhibition - Cyclin-Dependent Kinases (CDKs), and G1 Checkpoint
23. Topoisomerase-Induced DNA Damage and Therapeutic Potential
24. Polo-like Kinase 4 (PLK4) Inhibitors in Cancer Therapy
25. Synthetic Lethality by Poly (ADP-Ribose) Polymerase Inhibitors
26. Innovative Therapeutic Approaches